GALT peer analysis
Galectin Therapeutics (GALT) against its competitors: price, today's move, 1-year return and market value side by side.
- GALT's peers: ALT (Altimmune), AURA (Aura Biosciences), DMAC (DiaMedica Therapeutics), DRTS (Alpha Tau Medical), DSGN (Design Therapeutics), ENGN (enGene Therapeutics), LBRX (LB Pharmaceuticals), QSI (Quantum-Si).
GALT and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ALT Altimmune | $1.35 | -3.95% | -70.49% | $263.53M |
| AURA Aura Biosciences | $6.77 | -3.01% | 25.37% | $704.58M |
| DMAC DiaMedica Therapeutics | $8.26 | 2.99% | 13.15% | $445.69M |
| DRTS Alpha Tau Medical | $12.08 | 6.81% | 228.26% | $1.12B |
| DSGN Design Therapeutics | $9.02 | -3.22% | 22.89% | $577.61M |
| ENGN enGene Therapeutics | $1.70 | -3.41% | -74.85% | $113.93M |
| LBRX LB Pharmaceuticals | $38.85 | -2.97% | 144.72% | $1.26B |
| QSI Quantum-Si | $0.93 | -13.09% | -27.35% | $204.34M |
| RCKT Rocket Pharmaceuticals | $2.01 | -4.77% | -30.23% | $224.36M |
| GALT Galectin Therapeutics | $2.81 | -5.70% | -51.05% | $283.46M |